Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/20/2025

Management of Worsening Depression and Social Anxiety

Current Medication Assessment

  • The American Academy of Family Physicians suggests that trazodone 150mg at bedtime is being used appropriately for sleep 4
  • Low-dose quetiapine (25mg/day) is likely being used for additional anxiety management or sleep, as recommended by the American Academy of Family Physicians 4
  • The patient is already on the maximum recommended dose of escitalopram (20mg/day), which has shown efficacy for both depression and social anxiety disorder, according to the American Psychiatric Association 3
  • The American Psychological Association recommends that combination of SSRI with CBT has demonstrated superior efficacy compared to medication monotherapy for both depression and social anxiety 1
  • CBT is covered by national health insurance in many countries and can be provided by a physician or in collaboration with a nurse, as suggested by the American Psychological Association 1
  • The National Institute of Mental Health recommends that this approach addresses both pharmacological and psychological aspects of the disorders 1

Medication Change

  • The Mayo Clinic recommends switching to venlafaxine (SNRI) starting at 37.5mg once or twice daily, gradually increasing to a target dose of 150-225mg/day 5
  • Venlafaxine has shown efficacy in treatment-resistant depression and social anxiety that hasn't responded to SSRIs, according to the American College of Neuropsychopharmacology 2
  • The American Heart Association recommends monitoring for potential side effects including increased blood pressure and possible withdrawal symptoms if discontinued abruptly 5

Evidence for Recommendation

  • A study published in Neuropsychopharmacology showed that while escitalopram 10mg was not statistically superior to placebo for social anxiety, the 20mg dose (which the patient is already taking) showed significant improvement 3
  • The American College of Neuropsychopharmacology recommends that SNRIs like venlafaxine may have greater efficacy than SSRIs for patients with both depression and anxiety due to their dual action on serotonin and norepinephrine 2

Alternative Options

  • The American Academy of Family Physicians suggests considering a secondary amine tricyclic antidepressant such as nortriptyline (starting at 10mg at bedtime) or desipramine (10-25mg in the morning) 4
  • Mirtazapine (starting at 7.5mg at bedtime) could be considered, especially if sleep disturbance and poor appetite are prominent symptoms, as recommended by the American Academy of Family Physicians 4

Important Monitoring Considerations

  • The American Psychiatric Association recommends evaluating response to treatment every 2-4 weeks using standardized scales for depression and anxiety 2
  • The National Institute of Mental Health suggests monitoring for emergence or worsening of suicidal ideation, particularly during medication changes 2
  • The American Heart Association recommends monitoring blood pressure regularly for venlafaxine, as it can cause increases in some patients 5
  • The Mayo Clinic recommends considering obtaining a baseline ECG for patients over 40 years of age if switching to a TCA 7